Cue Biopharma, Inc. CUE

Cue Biopharma shares jumped 41.6% premarket after Phase 2 topline results for CUE-221 in moderate-to-severe chronic spontaneous urticaria. The Chinese study by Genesis Life Sciences enrolled 145 patients inadequately controlled by antihistamines. Primary and a key secondary endpoint were met with high statistical significance, and safety was favorable. The data suggest a potential clinical advantage vs omalizumab, but do not prove superiority. Results could support advancing CUE-221 into a Phase 2b/3 program for regulatory submission, though further data and regulatory discussions are needed. B. Riley started coverage with a Buy rating; markets broadly rose. The stock moved above its 52-week high of 45.50 premarket. A conference call is scheduled for 8:00 a.m. EDT to discuss magnitude and durability of responses, safety, and next-study design. Phase 2 topline results and potential move to Phase 2b/3 could improve upside but remain uncertain without clear superiority and full data.

Cue Biopharma announces positive topline results from CUE-221 Phase 2 study in Chronic Spontaneous Urticaria. Positive Phase 2 results for CUE-221 strengthen pipeline prospects and investor outlook for Cue Biopharma.

Cue Biopharma reported second quarter 2026 financial results and recent business highlights. Quarterly results plus business updates typically deliver moderate effects on valuation and investor outlook.

Cue Biopharma appoints James M. Ahlers as Chief Financial Officer and submits Investigational New Drug application for CUE-221. CFO appointment and CUE-221 IND filing represent major leadership and pipeline advancement steps.

Cue Biopharma, Inc. announces $50.0 million private placement. $50 million private placement delivers major capital infusion strengthening financial runway and development programs.

Cue Biopharma reported first quarter 2026 financial results and recent strategic developments. Quarterly financial results and strategic developments moderately affect financial performance and investor sentiment.

Cue Biopharma, Inc. (CUE) announces $30 million private placement led by existing healthcare-focused institutional investors, with proceeds funding clinical programs including CUE-101 and CUE-102, and general corporate purposes. $30 million private placement extends cash runway and funds key clinical trials, significantly impacting financial stability and development trajectory.

Cue Biopharma, Inc. (CUE) expands its immunotherapy pipeline through an exclusive worldwide license from Ascendant Health Sciences Ltd. for COMB-IG-001, a clinical-stage dual-mechanism anti-IgE antibody targeting allergies and asthma with both neutralizing and cell-depleting functions. Exclusive license for a clinical-stage anti-IgE antibody represents a major strategic pipeline expansion enhancing Cue Biopharma's immunotherapy portfolio and long-term growth potential.

Cue Biopharma, Inc. (CUE) appoints Shao-Lee Lin, M.D., Ph.D., as CEO, President, and Board Director to lead continued growth and transformation into a clinical-stage company. Appointing an experienced leader as CEO, President, and Board Director signals a major strategic push toward clinical-stage development, likely boosting investor sentiment and altering the company's trajectory.

Cue Biopharma, Inc. (CUE) announced a 1-for-30 reverse stock split. A 1-for-30 reverse stock split drastically consolidates shares to meet Nasdaq minimum bid price requirements, significantly altering share structure and investor perception.

Cue Biopharma, Inc. (CUE) appoints Lucinda Warren as Interim President and CEO. Interim CEO appointment signals potential leadership transition impacting strategic direction and investor sentiment.

Cue Biopharma to present new preclinical data on CUE-401, its lead autoimmune and inflammatory disease candidate, at IMMUNOLOGY2026. Preclinical data presentation on lead candidate at major conference offers moderate visibility and sentiment boost but limited by early-stage nature.

Cue Biopharma, Inc. (CUE) will receive a $7.5 million preclinical milestone payment from its collaboration and license agreement with Boehringer Ingelheim. $7.5 million non-dilutive funding from Boehringer Ingelheim validates Cue Biopharma's platform and strengthens its financial position for ongoing development.

Cue Biopharma, Inc. (CUE) announces CEO transition. CEO transitions signal major leadership changes that can significantly alter strategic direction and investor sentiment in biotech firms.

Cue Biopharma, Inc. (CUE) reported fourth quarter and full year 2025 financial results, highlighting business progress including clinical trial advancements and strategic updates. Financial results and business highlights disclose critical pipeline developments and operational status directly influencing investor sentiment and stock trajectory.

Cue Biopharma, Inc. has appointed Lucinda Warren as Chief Financial and Business Officer. Warren brings over 25 years of experience in finance and business development within the biotechnology and pharmaceutical sectors. Her previous roles include senior positions at various biotech companies, where she successfully led financial strategies and operations. This appointment is expected to enhance Cue Biopharma's strategic initiatives and financial management as the company continues to advance its innovative therapies. The appointment of an experienced executive may positively influence Cue Biopharma's operational effectiveness and strategic direction.

Cue Biopharma, Inc. has announced the pricing of a public offering amounting to $10 million. The offering consists of 2 million shares priced at $5 per share, with an option for underwriters to purchase an additional 300,000 shares. The proceeds from the offering are intended to be used for general corporate purposes, including funding research and development activities. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. The public offering may provide necessary funding for research and development, impacting financial performance and investor sentiment moderately.

Cue Biopharma, Inc. has announced a proposed public offering of its common stock, intending to raise funds for general corporate purposes, including advancing its drug development pipeline. The offering's details, including the number of shares and pricing, have not yet been disclosed. The company plans to use the proceeds to support its ongoing clinical trials and research initiatives. The public offering may provide necessary funding for clinical trials, impacting financial performance and product development.

ImmunoScape, based in Singapore, has announced a significant licensing deal aimed at advancing next-generation cell therapy for solid tumors. The company has also appointed new members to its board and scientific advisory board, signaling a strategic push to enhance its capabilities in the competitive field of cancer treatment. The licensing deal and new appointments indicate a strategic shift that could significantly enhance ImmunoScape's competitive position and market dynamics in cancer therapies.

Cue Biopharma, Inc. reported its financial results for the third quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its proprietary therapeutic platform, focusing on innovative treatments for various diseases. Recent collaborations and research initiatives were also emphasized, showcasing Cue Biopharma's commitment to expanding its pipeline and market presence. Significant advancements in product development and strategic collaborations are likely to impact future performance and investor sentiment.

Cue Biopharma, Inc. reported a loss for Q3, falling short of revenue estimates. The company continues to face challenges in its financial performance, which may affect investor sentiment and future operations. Despite ongoing efforts in product development, the results indicate a need for strategic reassessment to improve market positioning. The financial shortfall may moderately influence investor sentiment and operational strategies moving forward.

Cue Biopharma, Inc. has entered into a strategic collaboration with ImmunoScape to develop an innovative cell therapy approach targeting solid tumors. This partnership aims to leverage both companies' expertise in immunotherapy and cell-based treatments to enhance therapeutic options for cancer patients. The collaboration is expected to accelerate the development of breakthrough therapies that could significantly improve patient outcomes in oncology. The collaboration with ImmunoScape represents a significant strategic move that could enhance Cue Biopharma's product offerings and market position in the oncology sector.

Cue Biopharma, Inc. has announced a strategic leadership transition aimed at enhancing its growth trajectory with innovative autoimmune therapeutic candidates. This move is expected to position the company for its next phase of development and capitalize on its disruptive technologies in the healthcare sector. The leadership transition is a significant strategic move that could greatly influence the company's future performance and market positioning.

Cue Biopharma, Inc. has announced the initiation of an investigator-sponsored trial for CUE-102, a treatment targeting recurrent glioblastoma multiforme. This trial aims to evaluate the safety and efficacy of CUE-102 in patients with this aggressive form of brain cancer. The study is expected to provide valuable insights into the therapeutic potential of CUE-102 and its impact on patient outcomes. The initiation of a trial for a novel treatment in a challenging disease area like glioblastoma multiforme could significantly influence Cue Biopharma's future prospects and market performance.

Cue Biopharma, Inc. reported a loss for Q2 but exceeded revenue estimates, indicating a positive reception in the market despite the financial setback. The company continues to focus on its innovative therapies and pipeline development, which may influence future performance. Exceeding revenue estimates while reporting a loss suggests moderate influence on financial performance and market sentiment.

Cue Biopharma, Inc. reported its financial results for the second quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its proprietary therapeutic platform aimed at treating various diseases. Recent collaborations and research initiatives were also noted, indicating progress in its pipeline and strategic direction. Recent collaborations and advancements in the therapeutic pipeline may moderately influence financial performance and market positioning.

Cue Biopharma, Inc. reported a new complete response in a patient with recurrent metastatic HPV+ head and neck cancer during its Phase 1 trial of CUE-101 combined with pembrolizumab. The trial showed a confirmed overall response rate of 50% in patients with a combined positive score (CPS) ≥1, including those with low CPS (1-19). The 12-month overall survival rate was 88%, with a median overall survival of 32 months. The data suggests that CUE-101 may represent a breakthrough therapeutic approach, potentially establishing a new standard of care for this patient population. The reported clinical results indicate significant improvements in response rates and survival metrics, suggesting a major advancement in treatment options for HPV+ head and neck cancer.

Cue Biopharma, Inc. provided an update on its clinical stage asset, CUE-101, presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies. The presentation highlighted the potential of CUE-101 in treating cancer, emphasizing its innovative approach and the promising results observed in clinical trials. This update is part of Cue Biopharma's ongoing efforts to advance its pipeline and engage with the medical community. The presentation of CUE-101 at a significant summit indicates a strategic move that could enhance investor sentiment and market positioning.

Cue Biopharma, Inc. has received Pre-IND feedback from the FDA regarding its lead autoimmune asset, CUE-401, a bispecific molecule aimed at inducing and expanding regulatory T cells to treat autoimmune diseases. The FDA reviewed the trial design, dose escalation plan, and safety monitoring, allowing Cue Biopharma to proceed with an IND submission after completing final studies. The company believes CUE-401's unique mechanism could provide long-lasting immune tolerance and address significant disease indications. FDA feedback on CUE-401's development plan is a significant step towards potential regulatory approval and market introduction.

Cue Biopharma, Inc. (CUE) reported a Q1 loss of $0.17 per share, missing the Zacks Consensus Estimate of a loss of $0.14, and compared to a loss of $0.25 per share a year ago. Revenues of $0.42 million also fell short of estimates by 78.95%, down from $1.72 million year-over-year. The company has surpassed consensus EPS estimates three times in the last four quarters but has seen its shares decline by 28.5% this year. Despite the underperformance, the earnings outlook is currently favorable, resulting in a Zacks Rank #2 (Buy). The consensus EPS estimate for the next quarter is -$0.14 on $2 million in revenues, while the fiscal year estimate is -$0.58 on $8.36 million in revenues. The Medical - Biomedical and Genetics industry ranks in the top 34% of Zacks industries. The earnings miss and revenue shortfall indicate challenges, but the favorable earnings outlook suggests potential for moderate recovery.